Novazym offers monoclonal antibody (mAb) development in mice with guaranteed success based on standard endpoints or customer's specific applications. Our high rate of success, short turn-around time and affordable cost are due to our proprietary hybridoma technology, state-of the-art, specific pathogen free (SPF) facility, extensive experience in antibody production for over 500 gene targets, and flexibility to suit our customer's needs.


Wyświetlanie jednego wyniku